| Record ID | marc_columbia/Columbia-extract-20221130-009.mrc:28085030:1234 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-009.mrc:28085030:1234?format=raw |
LEADER: 01234cam a22003011 4500
001 4027164
005 20221027021408.0
008 810815s1944 xx a 000 0 eng d
010 $a 45003872
035 $a(OCoLC)ocm14746532
035 $9AJY5372HS
035 $a(NNC)4027164
035 $a4027164
040 $aNLM$cNLM$dMDU$dZCH
050 0 $aRC124$b.S38 1944
060 00 $aWC 245$bS424c 1944
082 0 $a616.82
110 1 $aGreat Britain.$bDepartment of Health for Scotland.$bScientific Advisory Committee on Medical Administration and Investigation.
245 10 $aSulphonamides in the treatment of meningococcal meningitis ;$breport to the Scientific Advisory Committee /$c[by the Infectious Diseases Sub-Committee]
260 $aEdinburgh,$c1944.
300 $a19 pages :$billustrations
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
500 $a1947 report issued with title: Cerebrospinal fever.
650 2 $aSulfonamides$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D013449Q000627
650 0 $aMeningitis, Cerebrospinal.$0http://id.loc.gov/authorities/subjects/sh85083564
650 0 $aSulfonamides.$0http://id.loc.gov/authorities/subjects/sh85130353
852 00 $boff,hsl$hRC124$i.Sco8